This move is archived. Current quotes and coverage live on the stock page.
Follow HBP
Helix BioPharma Corp. faced a significant downturn, closing down 3.16% in the latest trading session.
Helix BioPharma Corp. (HBP.TO) had a tough day on the TSX, with its stock price dropping to CA$1.53, a decline of 3.16%. Investors are concerned about what this means for the company's financial health and future prospects.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$84.02M
52W high
$5.40
52W low
$1.10
1W change
-21.43%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 127.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+127.3% Upside
Current Price
C$1.10
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
99.0%
Annualized
90-Day Vol
67.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.92
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.04 | C$0.74 – C$1.46 |
| 60 trading days | C$0.98 | C$0.60 – C$1.58 |
| 90 trading days | C$0.92 | C$0.51 – C$1.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent drop in Helix BioPharma's stock highlights the volatility of biotech investments, especially for companies still developing their products without consistent revenue streams.
Stock Drops 3.16% in One Day
Helix BioPharma's market cap is now about CA$120.68 million, reflecting investor caution amid ongoing financial challenges.
Bull case
If Helix can secure the financing it needs to advance its drug development and meet its strategic goals, the stock could recover significantly, drawing renewed interest from investors.
Bear case
On the other hand, ongoing financial losses and uncertainty about its drug pipeline could further shake investor confidence, potentially leading to larger declines in stock price.
Market Reaction to Financial Results
Advertisement
Even without recent news releases, the market's response to Helix BioPharma's past financial results is still affecting investor sentiment. The company reported a net loss of $5.2 million for the fiscal year ending July 31, 2025, raising concerns about its ability to keep operating without additional funding.
Challenges Ahead for Helix BioPharma
Helix BioPharma is navigating a tough landscape as it focuses on developing L-DOS47 as a treatment for Non-Small Cell Lung Carcinoma. The lack of immediate revenue and ongoing losses present significant risks that investors need to consider when evaluating the stock's potential.
Investor Sentiment and Future Outlook
The recent drop in stock price reflects a growing skepticism among investors about Helix BioPharma's future. As the company works to advance its drug development efforts, securing financing will be crucial to turning things around.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
